MiNK Therapeutics (INKT) Share-based Compensation (2020 - 2026)
MiNK Therapeutics (INKT) posted Share-based Compensation of $630382.0 for Q1 2026, up 7.21% sequentially from $587997.0 in Q4 2025, and up 10.4% YoY from $571000.0 in Q1 2025.
MiNK Therapeutics (INKT) Share-based Compensation (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $630382.0 in Q1 2026.
- Quarterly Share-based Compensation rose 10.4% year-over-year to $630382.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 307.59% YoY) and the FY2025 annual result came in at $2.7 million, up 16.26% from the prior year.
- Share-based Compensation climbed to $630382.0 in Q1 2026 per INKT's latest filing, from $587997.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.1 million in Q4 2023 and troughed at -$2.3 million in Q4 2024.
- A 5-year average of $133289.1 and a median of $33328.0 in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 2566.55% in 2024, down 312.93% in 2024.
- Over 5 years, Share-based Compensation stood at -$197511.0 in 2022, then soared by 657.62% to $1.1 million in 2023, then sank by 312.93% to -$2.3 million in 2024, then surged by 125.07% to $587997.0 in 2025, then rose by 7.21% to $630382.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $630382.0, $587997.0, and $800000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | 630,382.00 |
| Mar 31, 2026 | 630,382.00 |
| Dec 31, 2025 | 587,997.00 |
| Dec 31, 2025 | 587,997.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 8,079.00 |
| Jun 30, 2025 | 8,079.00 |
| Mar 31, 2025 | 571,000.00 |
| Mar 31, 2025 | 571,000.00 |
| Dec 31, 2024 | -2.35 Mn |
| Dec 31, 2024 | -2.35 Mn |
| Sep 30, 2024 | 883,000.00 |
| Sep 30, 2024 | 883,000.00 |
| Jun 30, 2024 | 25,313.00 |
| Jun 30, 2024 | 25,313.00 |
| Mar 31, 2024 | 27,033.00 |
| Mar 31, 2024 | 27,033.00 |